Crestline Management LP Acquires 70,571 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Crestline Management LP lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 283.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 95,428 shares of the company's stock after acquiring an additional 70,571 shares during the quarter. Crestline Management LP owned about 0.11% of IDEAYA Biosciences worth $2,452,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in IDYA. Norges Bank bought a new stake in IDEAYA Biosciences during the fourth quarter valued at about $13,385,000. FMR LLC boosted its stake in IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after purchasing an additional 327,498 shares during the period. Vanguard Group Inc. boosted its stake in IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after purchasing an additional 282,936 shares during the period. WCM Investment Management LLC acquired a new stake in IDEAYA Biosciences in the 4th quarter valued at approximately $6,030,000. Finally, Adage Capital Partners GP L.L.C. increased its position in IDEAYA Biosciences by 22.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company's stock worth $30,842,000 after buying an additional 220,000 shares during the period. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Trading Down 3.7%

Shares of IDYA stock traded down $0.68 on Tuesday, hitting $17.67. The stock had a trading volume of 177,183 shares, compared to its average volume of 1,156,530. The firm has a market cap of $1.55 billion, a P/E ratio of -5.35 and a beta of 0.26. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42. The company has a fifty day moving average price of $17.72 and a two-hundred day moving average price of $22.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the company posted ($0.53) earnings per share. On average, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IDYA. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Stephens restated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.